These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 26155455)

  • 1. Phase III, randomized, double-blind, placebo-controlled, multicenter study of lipegfilgrastim in patients with non-small cell lung cancer receiving myelosuppressive therapy.
    Volovat C; Bondarenko IM; Gladkov OA; Elsässer R; Buchner A; Bias P; Müller U
    Springerplus; 2015; 4():316. PubMed ID: 26155455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of lipegfilgrastim compared with placebo in patients with non-small cell lung cancer receiving chemotherapy: post hoc analysis of elderly versus younger patients.
    Volovat C; Bondarenko I; Gladkov O; Buchner A; Lammerich A; Müller U; Bias P
    Support Care Cancer; 2016 Dec; 24(12):4913-4920. PubMed ID: 27501966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of lipegfilgrastim versus pegfilgrastim in elderly patients with aggressive B cell non-Hodgkin lymphoma (B-NHL): results of the randomized, open-label, non-inferiority AVOID neutropenia study.
    Link H; Illerhaus G; Martens UM; Salar A; Depenbusch R; Köhler A; Engelhardt M; Mahlmann S; Zaiss M; Lammerich A; Bias P; Buchner A
    Support Care Cancer; 2021 May; 29(5):2519-2527. PubMed ID: 32944800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, double-blind, active control, multicenter, dose-finding study of lipegfilgrastim (XM22) in breast cancer patients receiving myelosuppressive therapy.
    Buchner A; Elsässer R; Bias P
    Breast Cancer Res Treat; 2014 Nov; 148(1):107-16. PubMed ID: 25261291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Lipegfilgrastim in Lung Cancer Patients Receiving Myelosuppressive Chemotherapy in a Real-World Setting: Results of an Analysis of Pooled Data from Two Non-Interventional European Studies.
    Gessner C; Potthoff K; Frost N
    Oncol Res Treat; 2021; 44(3):93-102. PubMed ID: 33477145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipegfilgrastim in the management of chemotherapy-induced neutropenia of cancer patients.
    Guariglia R; Martorelli MC; Lerose R; Telesca D; Milella MR; Musto P
    Biologics; 2016; 10():1-8. PubMed ID: 26858523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase III Study of Balugrastim Versus Pegfilgrastim in Breast Cancer Patients Receiving Chemotherapy With Doxorubicin and Docetaxel.
    Gladkov O; Moiseyenko V; Bondarenko IN; Shparyk Y; Barash S; Adar L; Avisar N
    Oncologist; 2016 Jan; 21(1):7-15. PubMed ID: 26668251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotherapy-associated treatment burden in breast cancer patients receiving lipegfilgrastim or pegfilgrastim: secondary efficacy data from a phase III study.
    Gladkov OA; Buchner A; Bias P; Müller U; Elsässer R
    Support Care Cancer; 2016 Jan; 24(1):395-400. PubMed ID: 26092233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efbemalenograstim alfa, an Fc fusion protein, long-acting granulocyte-colony stimulating factor for reducing the risk of febrile neutropenia following chemotherapy: results of a phase III trial.
    Glaspy J; Bondarenko I; Burdaeva O; Chen J; Rutty D; Li R; Wang S; Hou Q; Li S
    Support Care Cancer; 2023 Dec; 32(1):34. PubMed ID: 38103088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prophylaxis of chemotherapy-induced neutropenia with lipegfilgrastim in patients with lung cancer: final results from the non-interventional study NADIR.
    Geßner C; Fietz T; Losem C; Lück A; Schulz H; Niemeier B; Groschek M; Eschenburg H; Weide R; Kretzschmar A; Frost N; Hipp J; Harde J; Matillon CD; Grebhardt S; Potthoff K
    Curr Med Res Opin; 2022 Dec; 38(12):2191-2199. PubMed ID: 36047998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prophylaxis of chemotherapy-induced neutropenia and febrile neutropenia with lipegfilgrastim in patients with non-Hodgkin lymphoma (NADIR study).
    Wolff T; Schulz H; Losem C; Reichert D; Hurtz HJ; Sandner R; Harde J; Grebhardt S; Potthoff K; Mueller U; Fietz T
    Eur J Haematol; 2019 Feb; 102(2):174-181. PubMed ID: 30347466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prophylaxis of chemotherapy-induced neutropenia and febrile neutropenia with lipegfilgrastim in 2489 cancer patients: final results from the non-interventional study NADIR.
    Fietz T; Lück A; Schulz H; Harde J; Losem C; Grebhardt S; Wolff T; Potthoff K; Müller U; Zaiss M; Kurbacher CM
    Curr Med Res Opin; 2019 Jul; 35(7):1127-1138. PubMed ID: 30557099
    [No Abstract]   [Full Text] [Related]  

  • 13. Incidence of bone pain in patients with breast cancer treated with lipegfilgrastim or pegfilgrastim: an integrated analysis from phase II and III studies.
    Bondarenko IM; Bias P; Buchner A
    Support Care Cancer; 2016 Jan; 24(1):267-273. PubMed ID: 26024743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meta-analysis and indirect treatment comparison of lipegfilgrastim with pegfilgrastim and filgrastim for the reduction of chemotherapy-induced neutropenia-related events.
    Bond TC; Szabo E; Gabriel S; Klastersky J; Tomey O; Mueller U; Schwartzberg L; Tang B
    J Oncol Pharm Pract; 2018 Sep; 24(6):412-423. PubMed ID: 28614980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Utility Analysis of Lipegfilgrastim Compared to Pegfilgrastim for the Prophylaxis of Chemotherapy-Induced Neutropenia in Patients with Stage II-IV Breast Cancer.
    Akpo EIH; Jansen IR; Maes E; Simoens S
    Front Pharmacol; 2017; 8():614. PubMed ID: 28955224
    [No Abstract]   [Full Text] [Related]  

  • 16. Immunogenicity Assessment of Lipegfilgrastim in Patients with Breast Cancer Receiving Chemotherapy.
    Zou L; Buchner A; Roberge M; Liu PM
    J Immunol Res; 2016; 2016():9248061. PubMed ID: 27419145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of chemotherapy-induced neutropenia pegylated recombinant human granulocyte colony-stimulating factor: a multi-center randomized controlled phase II clinical study].
    Shi YK; He XH; Yang S; Wang HQ; Jiang ZF; Zhu YZ; Ke XY; Zhang Y; Liu YP; Zhang WJ; Wang Z; Shi QZ; Xie XD; Zhang HL; Wang JJ; Luo DY; Zheng QS; Sun RY
    Zhonghua Yi Xue Za Zhi; 2006 Dec; 86(48):3414-9. PubMed ID: 17313855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NADIR: A Non-Interventional Study on the Prophylaxis of Chemotherapy-Induced Neutropenia Using Lipegfilgrastim - First Interim Analysis.
    Kurbacher CM; Fietz T; Diel IJ; Egert M; Hurtz HJ; Lück A; Weide R; Salat C; Wolff T; Zaiss M; Klare P; Losem C; Illmer T; Weißenborn G; Steffens CC; Schulze M; Tesch H; Oskay-Oezcelik G; Teichmann B; Harde J; Scheuerlein RW
    Oncol Res Treat; 2015; 38(5):221-9. PubMed ID: 25966769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of balugrastim compared with pegfilgrastim in patients with breast cancer receiving chemotherapy.
    Volovat C; Gladkov OA; Bondarenko IM; Barash S; Buchner A; Bias P; Adar L; Avisar N
    Clin Breast Cancer; 2014 Apr; 14(2):101-8. PubMed ID: 24485296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipegfilgrastim: pharmacodynamics and pharmacokinetics for body-weight-adjusted and 6 mg fixed doses in two randomized studies in healthy volunteers.
    Buchner A; Lammerich A; Abdolzade-Bavil A; Müller U; Bias P
    Curr Med Res Opin; 2014 Dec; 30(12):2523-33. PubMed ID: 25251999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.